Podcasts about Fluoxetine

In this powerful and honest episode of The Penis Project Podcast, Melissa Hadley Barrett speaks with Dave and his partner Jen about their journey dealing with premature ejaculation (PE) — a common but often misunderstood sexual health condition affecting many men and couples.  Dave opens up about his experience living with PE since adolescence, the impact it had on his confidence and relationship, and how alcohol became a coping mechanism. With courage and persistence, Dave eventually found the right healthcare support, the right SSRI medication, and a path forward that improved both his sexual function and emotional connection with his partner.  Together, Melissa, Dave and Jen dive deep into the emotional, psychological, and physical sides of premature ejaculation — offering valuable insights for men, couples, and practitioners alike.  In This Episode, We Cover:  What premature ejaculation really is – and what it isn't  The difference between primary and secondary PE  Why many men are misinformed or dismissed by health professionals  The impact of PE on relationships, communication, and self-esteem  Dave's journey through trial-and-error with various SSRIs: Priligy (Dapoxetine), Paroxetine, Fluoxetine and Escitalopram (Lexapro)  The hidden cost of online treatment platforms – and why cheaper, more ethical options exist  How the right treatment changed everything – from sex drive to emotional closeness  Jen's reflections as a partner and the importance of support, understanding and touch  How couples can reconnect through small changes, time together, and deeper conversations  Melissa's recommendation: Sanctuary of Ananda for Tantra-based relationship connection workshops  Key Takeaways:    Premature ejaculation is more common than you think – and it's treatable  Not all SSRIs are the same. Personalised treatment matters.  The emotional and relational impacts of PE are real – and deserve attention  There's no shame in asking for help. Support is available, affordable, and effective.  Sexual health is about more than performance – it's about connection, confidence, and communication  Expert Insight from Melissa Hadley Barrett:  “If PE is affecting your confidence, relationship or sex life – there is help. You don't need to suffer in silence. With the right support, treatment can be simple, effective, and affordable.”  Resources & Links:  Book a telehealth consult with our sexual health nurse practitioners at Restorative Health Clinic  Learn more about Sanctuary of Ananda – Tantra and connection workshops for couples  Listen to Cam Fraser's podcast on modern masculinity and sexual wellness  For more information check out our websites www.rshealth.com.au , www.makehardeasy.com.au and www.melissahadleybarrett.com.au   Listen & Subscribe  If you found this episode helpful, don't forget to subscribe, rate, and review the podcast! Your feedback helps us continue bringing important conversations to light. Search for The Penis Project Podcast on Spotify, Apple Podcasts, or your favourite podcast app.  Connect With Us  Have questions or want to share your story?  Email: admin@melissahadleybarrett.com  Website: www.rshealth.com.au  Websites:  https://rshealth.com.au/  All genders  https://makehardeasy.com.au   https://melissahadleybarrett.com   http://www.menshealthphysiotherapy.com.au/  http://prost.com.au/     Facebook:  https://m.facebook.com/p/Melissa-Hadley-Barrett-100085237672685/  https://www.facebook.com/profile.php?id=100085146627814    Instagram:  https://www.instagram.com/melissahadleybarrett/  https://www.instagram.com/restorativehealth.clinic/  TikTok: @melissahadleybarrett  YouTube: Melissa Hadley Barrett  Linkedin:  https://www.linkedin.com/in/melissa-hadley-barrett/   TEDX  https://www.youtube.com/watch?v=IjHj1YTmLoA 

In episode 279 of The Just Checking In Podcast we checked in with Leah Morris. Leah currently works as a Centre Manager at the Liverpool branch of James' Place UK, a charity who are doing lifesaving work for men's mental health. Leah was diagnosed with Generalised Anxiety Disorder (GAD) in her early 20s after experiencing some workplace bullying in a previous role prior to joining James' Place UK. Prior to that, she had experienced panic attacks as a teenager whilst studying for her GCSEs but didn't know what they were at the time. After she was diagnosed with GAD, she was prescribed medication in 2019, specifically Fluoxetine which she said helped get her back to a baseline level and she has now been off medication in 2020. At the heart of her mental health recovery has been fitness and exercise. Before the Covid-19 pandemic, she started running, doing the ‘couch to 5k' programme. She got to the point where she was running 5ks three times a week for a year. However, in Christmas 2021, she bought a house and stopped running when she was dealing with the upheaval that moving house brings. She tried picking up running again in 2022 but couldn't get back into it. In May 2023, she joined James' Place UK and at the start of 2024, she got back into fitness, this time trying swimming to help her mental health. She found her rhythm again and now swims three times a week at time of recording. In this episode we talk about Leah's anxiety, workplace bullying, the role fitness played in her recovery and the importance of having the right support network around you to maintain or boost your mental health. As always, #itsokaytovent Support Us: Patreon: www.patreon.com/venthelpuk GoFundMe: www.gofundme.com/f/help-vent-supp…ir-mental-health Merchandise: www.redbubble.com/people/VentUK/shop Music: @patawawa - Strange: www.youtube.com/watch?v=d70wfeJSEvk

Dr. Larry Wang will be hosting todays episode with a very special guest. . . another Dr. Larry Wang? . . . Bipolar depression being treated with an antidepressant? Welcome to the multiverse.

This podcast features Dr. Chadi Calarge, a child psychiatrist at Baylor College of Medicine and, for over 20 years, a researcher focused on long-term psychiatric medication safety with regard to height growth and metabolic abnormalities. He gives an overview of past and forward-looking research questions related to growth, growth hormones, and such drugs as selective serotonin reuptake inhibitors and stimulants. He discusses the journal article, “Fluoxetine and Sertraline Inhibit Height Growth and Growth Hormone Signaling During Puberty,” which was written with 10 co-authors and is published in the November-December 2024 issue of the Journal of Clinical Psychopharmacology.

In this episode, Tristan J. Barber, MA, MD, FRCP, and Glenn J. Treisman, MD, PhD, discuss the importance of screening, diagnosing, and treating PTSD in people with HIV. They illustrate their discussion through a patient case and provide strategies for accomplishing this, sharing their own experiences and approaches to thinking about PTSD, structuring appointments, and integrating care. Presenters:Tristan J. Barber, MA, MD, FRCPConsultant in HIV MedicineRoyal Free London NHS Foundation TrustHonorary Associate ProfessorInstitute for Global HealthUniversity College LondonLondon, United KingdomGlenn J. Treisman, MD, PhDEugene Meyer III Professor of Psychiatry and MedicineJohns Hopkins University School of MedicineBaltimore, MarylandDownloadable slides:https://bit.ly/4dBu929Program:https://bit.ly/3WB2VCO

This episode is sponsored by Freed - Freed is an amazing time saver for busy healthcare professionals! It listens, transcribes, and writes medical notes for you! Go check them out and support our sponsor! In this episode, we highlight some of the most important clinical pearls on the following medications; nitrofurantoin, fentanyl patches, isosorbide mononitrate, fluoxetine, and triamcinolone. Nitrofurantoin is an antibiotic used for UTIs. We need to be careful with this medication in patients with CKD. Fentanyl is an opioid. There are many clinical quirks with fentanyl patches. For a full rundown, check out this previous podcast episode. Isosorbide mononitrate is a nitrate medication so we need to be careful with the use of PDE-5 inhibitors. Fluoxetine is an SSRI. It has a longer half-life than most SSRIs. I discuss what that means in this episode. Triamcinolone (topical) is most frequently used for redness, itching, and skin irritation.

Internationally renowned bipolar disorder expert Dr. Trisha Suppes unravels the latest science in bipolar disorder treatment by breaking down the proven and cutting-edge treatments available today - exploring traditional solutions such as Lithium and mood stabilizers alongside exciting new options like psilocybin, ketamine, and the Ketogenic diet. Dr. Suppes also navigates the complexities of mania and tackles the perennial question: is lifelong medication necessary to live well with bipolar disorder? (00:00) About Dr. Suppes Medication Treatments (03:00) Is Lithium the Gold Standard? (05:22) Atypical Antipsychotics (07:22) Dangers of Antidepressants? (09:17) Medications Lose Strength? Non-medication Treatments (10:47) Psychotherapy (12:54) Ketogenic Diet & Nutrition (13:28) Cannabis (14:20) Ketamine Brain Stimulation Therapies (15:18) rTMS (Transcranial Magnetic Stimulation) (16:01) VNS (Vagus Nerve Stimulation) (17:07) ECT (Electroconvulsive Therapy) Bipolar Disorder is Complex (18:52) Insight & Denying Bipolar Disorder (22:45) Bipolar I: Need Meds Forever? (23:44) Bipolar II: Need Meds Forever? (26:22) Hypomania Causes Misdiagnosis (28:16) Mixed States Psychedelics (29:28) Psilocybin & Magic Mushrooms (32:33) Microdosing & LSD (34:02) MDMA Closing (35:41) Keeping You "A Little Depressed" (37:55) Why Recovery Is Possible (39:06) Reflecting on Research Impact Dr. Trisha Suppes, M.D., Ph.D., is a distinguished expert on the biology and treatment of bipolar disorder, and mood disorders generally. Dr. Suppes is the Director of Exploratory Therapeutics and Professor at Stanford University in the School of Medicine. At the VA Palo Alto Health Care System, she is Director of the CSP NODES and is the Founder of the Bipolar and Depression Research Program. Her areas of expertise include long-term treatment strategies for bipolar disorder, identification and treatment of bipolar II disorder, treatment of those with bipolar disorders and co-morbid conditions and use of complementary medicine. She has recently launched a new initiative to explore the use of psychedelics for mood disorders and PTSD in Veterans. Dr. Suppes has been integrally involved in numerous initiatives to improve evidence-based treatment for bipolar disorders. Dr. Suppes participated as a member of the DSM-5 Mood Disorders committee on updating the APA DSM-5 criteria for Mood Disorders and was chair of the APA DSM-5 Bipolar Disorder subcommittee. She was the past President of the International Society of Bipolar Disorders (ISBD). Treatments Referenced

Dans cet épisode captivant, plongez-vous dans un univers de guérison et de transformation avec notre duo mère-fille. Ensemble, elles explorent les multiples avenues et thérapies déployées pour surmonter les traumatismes. Laurie-Raphaëlle et Marie-Claude partagent avec passion leur propre voyage à travers la thérapie EMDR (Eye-Movement Desensitization and Reprocessing), une méthode puissante de libération émotionnelle. Découvrez avec elles les fondements de cette approche et plongez au cœur d'une séance. Mais ce n'est pas tout ! Elles vous entraînent également dans un monde d'activités stimulantes qui nourrissent votre concentration et renforcent le lien entre votre corps et votre esprit. Et que dire des avancées révolutionnaires en cours ? On aborde le Neurofeedback et la thérapie de reconsolidation (Méthode Brunet) qui ouvrent de nouvelles portes vers la résilience et le bien-être. Ready to shine? Let's go! Références:1) Dr. Bessel Van Der Kolk, « Le corps n'oublie rien. Le cerveau, l'esprit, le corps dans la guérison du traumatisme », Albin Michel, 2018.2) Institut Universitaire en santé mentale de Montréal, « État de stress post-traumatique, 2018.3) Mc Cafferty, Ian, « In safe hands: Massage and PTST », 2016.4) B. Van Der Kolk et al., « Yoga as an Adjunctive Therapy for PTSD» Journal of Clinical Psychiatry, 75, no.6, 2014.5) R. Bradlet et al., « A Multidimensional Meta-Analysis of Psychotherapy for PTSD», American Journal of Psychiatry, 162, no.2, 2005.6) B. Van Der Kolk et al., « A Randomized Clinical Trial of EMDR, Fluoxetine, and pill Placebo in the treatment of PTSD: Treatment Effects and Long-Term Maintenance », Journal of Clinical Psychiatry, 68, no.1, 2007. 7) M. Hollifield et al., « Acupuncture for PTSD: A Randomized Controlled Pilot Trial », Journal of Nervous and Mental Disease, 195, no.6, 2007.8) Radio Canada, « Le psychologue qui soigne le choc post-traumatique en 6 semaines », Audio fil du 4 décembre 2018.9) EMDR Canada, site internet10) Ordre des Psychologues du Québec, site internet Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Join us for a brief review of Fluoxetine (Prozac).

High Yield Psychiatric Medications Antidepressants Review for your PANCE, PANRE, Eor's and other Physician Assistant exams. Review includes SSRI's, SNRIs, TCAs, MAOIs, Atypical antidepressants, Serotonin modulators. TrueLearn PANCE/PANRE SmartBank:https://truelearn.referralrock.com/l/CRAMTHEPANCE/Discount code for 20% off: CRAMTHEPANCEIncluded in review: Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Desvenlafaxine, Duloxetine, Levomilnacipran , Milnacipran, Venlafaxine, Amitriptyline, Clomipramine, Doxepin, Imipramine, Trimipramine, Desipramine, Nortriptyline, Protriptyline, Tranylcypromine, Isocarboxazid, Phenelzine Selegiline, Bupropion, Mirtazapine, Trazodone

On today's podcast Dr. Gillett and James O'Hara NP, discuss Pre-Menstrual Dysphoric Disorder. They do a comprehensive "Non-Systematic Review". 00:00 Intro00:29 Differences in treatment for PMDD and sex offenders: explores the contrasting approaches to treating Premenstrual Dysphoric Disorder (PMDD) and sex offenders, highlighting how the two conditions require very similar treatment strategies.02:12 Non-systematic review of the evidence: analysis of research and evidence related to PMDD and sex offender treatment13:21 SSRIs: (SSRIs), a type of antidepressant medication, and their role in the treatment of PMDD or possibly other conditions.17:58 Oral Contraceptives: discusses the use of oral contraceptives as a treatment option for PMDD or related topics.19:24 "Treatments with strong scientific evidence": This segment may list and discuss various treatment options that have a claimed robust scientific basis for their effectiveness in addressing PMDD or other conditions.21:50 Same heading more aggressive treatments: This section might delve into treatment options that are considered more aggressive in addressing PMDD or similar conditions, potentially involving interventions beyond medication.23:52 Treatments with limited but promising evidence: We explore treatment approaches with limited scientific support but "promising" in managing PMDD or related issues.32:20 Closest to the root cause: We discuss treatments that aim to address the underlying causes or mechanisms of PMDD rather than just alleviating symptoms.40:41 Not effective: Treatments or approaches that have been found to be ineffective in managing PMDD or related conditions.44:55 Dutasteride study: A specific study or research involving the use of Dutasteride, a medication often used for enlarged prostate, and its potential effects on PMDD or a related topic.47:38 Low dose of Fluoxetine: The use of a low dose of Fluoxetine, an SSRI, in the context of PMDD or another condition.49:19 Effects of acute estradiol and progesterone/Suicidal: The effects of acute administration of estradiol and progesterone and their potential connection to suicidal tendencies or related issues.1:00:25 Outro:For High-quality labs:► https://gilletthealth.com/order-lab-panels/For information on the Gillett Health clinic, lab panels, and health coaching:► https://GillettHealth.comFollow Gillett Health for more content from James and Kyle► https://instagram.com/gilletthealth► https://www.tiktok.com/@gilletthealth► https://twitter.com/gilletthealth► https://www.facebook.com/gilletthealthFollow Kyle Gillett, MD► https://instagram.com/kylegillettmdFollow James O'Hara, NP► https://Instagram.com/jamesoharanpFor 10% off Gorilla Mind products including SIGMA: Use code “GH10”► https://gorillamind.com/For discounts on high-quality supplements►https://www.thorne.com/u/GillettHealth#podcast #womenshealth #hormones #female #women #gilletthealthAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.07.18.549528v1?rss=1 Authors: Antunes, D. F., Stettler, P. R., Taborsky, B. Abstract: Behavioural interactions between conspecifics rely on the appreciation of social cues, which is achieved through biochemical switching of pre-existing neurophysiological pathways. Serotonin is one of the major neurotransmitters in the central nervous system responsible for the modulation of physiological and behavioural traits, in particular social behaviour. The importance of serotonin for the ability to optimise one's social behaviour depending on available social information, that is, social competence, is yet unknown. Here we investigate how serotonin and the serotonin 1A receptor (5-HT1A) modulate social competence in a competitive context. In the cooperatively breeding cichlid Neolamprologus pulcher, we pharmacologically manipulated theserotonin availability and 5-HT1A activity to test their effects on social behaviours during an asymmetric contest between the owner of a defended territory containing shelter and an intruder devoid of a territory. In this contest, the adequate response by the intruders, the focal individuals in our study, is to show submissive behaviour in order to avoid eviction from the vicinity of the shelter. While the serotonin enhancer Fluoxetine did not affect the frequency of submission towards territory owners, reducing serotonin by a low dosage of 4-Chloro-DL-phenylalanine (PCPA) increased submissive behaviour. Furthermore, threat displays towards territory owners were reduced at high dosages of Fluoxetine and also at the lowest dosage of PCPA. 5-HT1A activation increased threat displays by intruders, indicating that this receptor may not be involved in regulating social competence. We conclude that serotonin, but not its receptor 5-HT1A plays an important role in the regulation of social competence. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Visit: https://nursing.com/140meds to request your free copy of "140 Must Know Meds" Generic Name Fluoxetine Trade Name Prozac Indication Depressive disorder, OCD, bulimia, panic disorder, bipolar, anorexia, ADHD, DM neuropathy, obesity Action Inhibits reuptake of serotonin allowing it to persist longer in the synaptic cleft Therapeutic Class Antidepressant Pharmacologic Class SSRI Nursing Considerations • Do not use while taking MAOIs • May cause suicidal thoughts, drowsiness, anxiety, sexual dysfunction, insomnia, palpitations • Monitor closely for serotonin syndrome • Concurrent use with certain medications may lead to QT prolongation • Monitor mood changes and assess for suicidal ideation • Monitor nutrition status • May cause elevated liver enzymes • Instruct pt to maintain good oral hygiene

https://302.buzz/PM-WhatAreYourThoughtsDr. Brooks Keeshin, a triple-board trained child psychiatrist with a focus on trauma, shares his journey into child psychiatry, and discusses the idea of it being a subspecialty of pediatrics. The conversation leads to a discussion on the role of pediatricians in prescribing psychotropic medication and the importance of identifying and recognizing mental health concerns in children. Dr. Keeshin highlights the pitfalls of thinking about mental health as a catch-all, and reminds pediatricians to consider individual diagnoses to guide treatment options. He also points out that psychotherapeutic interventions are usually at the top of the list, and that medication is only one consideration. Get your pencils out…. You'll want to take notes… [00:33 -13:56] The Importance of Identifying Mental Health ConcernsIdentifying mental health concerns should begin with listening to the family's concerns and the child's or adolescent's voice.Using measurements such as universal screening or targeted screeners can help inform the differential diagnosis.It is important to move away from the thinking that mental health is a catch-all, and instead focus on individual diagnoses that will guide treatment recommendations.Early identification and treatment of mental health concerns can improve outcomes and prevent future problems.Having a process to rule out other contributing factors to distress, such as adjustment disorders, can lead to more accurate diagnoses and effective treatment.[13:57 - 26:01] Choosing Treatment Options for Pediatric Anxiety The importance of getting a full picture of the child's symptoms, including using screeners such as SCAREDConsidering evidence-based interventions for pediatric anxiety, such as anxiety-focused CBT or SSRIsCombination therapy with psychotherapeutic intervention and SSRIs may offer the best chance of complete remissionSSRIs such as Fluoxetine, Sertraline, and Citalopram have the greatest evidence base and experience in youthAssessing the level of impairment and degree of symptoms in making a decision about medication vs. psychotherapeutic intervention[26:02 -38:10] Addressing Anxiety Symptoms in Traumatized KidsStepped approach involves addressing other contributing factors before using SSRIsEnsure physical safety of environment before trauma-focused therapyAddress sleep first as chronic insomnia can drive anxiety symptomsMaximize other interventions like social determinants of health and trauma therapy before giving SSRIsAggressively titrate SSRIs to effective doses for robust response[28:11 - 51:33] Improving Access to Expert Child Psychiatric CareImproving access to comprehensive psychiatric evaluations by child psychiatrists is essential for identifying children with severe psychiatric needs.The limited number of child psychiatrists means better triage is needed to ensure the most severely impacted children receive the necessary care.Educating child psychiatrists about the comfort levels and limitations of ongoing psychiatric treatment in primary care can be helpful in improving collaboration.Consider outpatient programs or day treatment programs for kids after inpatient treatment to help them prepare for a return to their normal life.Consider partnering with primary care if it would be more appropriate for the child in the long term.[51:34 - 59:59] Closing segment TakeawayLinks to resources mentioned on the...

Should you take an Anti-Depressant? Let's find out... --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/chris-levine/support

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.01.23.525169v1?rss=1 Authors: Bigot, M., De Badts, C.-H., Benchetrit, A., Vicq, E., Moigneu, C., Meyrel, M., Wagner, S., Houenou, J., Lledo, P.-M., Henry, C., ALONSO, M. Abstract: Negative emotional bias is an essential hallmark of depression reflected by negative shift in hedonic valence assignment to emotional stimuli. Pleasant cues become less attractive and unpleasant ones more aversive. Given the crucial role of amygdala in valence coding, we hypothesize that specific basolateral amygdala (BLA) circuits alterations might support negative emotional bias associated with depressive states. Using a translational assay, we evaluate odor valence assignment in an animal model for depression chronically administered by corticosterone (CORT). We show spontaneous negative bias in depressive-like mice that attribute more negative valences for both attractive and aversive odors, mimicking thus the bias observed in depressed bipolar patients. Combining CTB and rabies-based tracing with ex vivo measurements of neuronal activity and chemogenetics experiments, we find that the CORT treatment reduces BLA-to-nucleus accumbens (NAc) neuronal activity and increases BLA-to-central amygdala activity, circuits respectively known to be involved in positive and negative valence encoding. Alterations in presynaptic connectivity of BLA-projecting neurons accompany these activity shifts. Interestingly, inputs from the paraventricular thalamus nucleus (PVT) towards BLA-to-NAc neurons are reduced in CORT-treated mice. Finally, chemogenetically activating the BLA-to-NAc circuit attenuates the negative bias in CORT-treated mice as well as the depressive-like phenotype, similarly than Fluoxetine antidepressant treatment. Altogether, we demonstrate that depressive states are associated with negative emotional bias both in human and mice. This bias is supported by activity shifts of specific BLA circuits along with durable presynaptic connectivity changes, but it could be alleviated by antidepressant drug or activity manipulation of altered BLA circuit. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

In this episode we discuss the use of Fluoxetine (Prozac) for ADHD and Anxiety as Sparky tells us all about starting  the medication and what impact it had. Fluoxetine (Prozac) is an SSRI Anti Depressant medication prescribed for depression and anxiety based disorders. There is some emerging studies showing evidence to suggest it can help with ADHD symptoms too (although it is very small)Sparky discusses the positive effects of Fluoxetine, the side effects, how he felt whilst on the medication, if it helped with his ADHD symptoms and anxiety! Shell starts another dose of Concerta and so clearly before you know it the conversation turns into rambling on how feel about IKEA!and.... back to meds!PROZAC, CONCERTA AND IKEA!Episode resourcesCheck out the website below to find useful linkshttps://www.adhdadult.uk/List of symptoms, diagnostic criteria for ADHD and further information:https://www.qandadhd.com/diagnostic-criteriaIf you identify with 5 symptoms on each list often, it may be something you want to speak to your doctor about.See you next week for another episode of shenanigans!We upload a new episode every Sunday evening.Our Socialswww.adopaminekick.comFollow us on Instagramwww.instagram.com/adopaminekickLike us on Facebookwww.facebook.com/adopaminekickEmail us: adopaminekick@gmail.comSupport the showIf you'd like to support the show please consider subscribing to us, it starts at $3 a month:BUZZSPROUT Subscriptionhttps://www.buzzsprout.com/1898728/supporters/newBuy Me A Coffeehttps://bmc.link/adopaminekickThanks so much to anyone that donates to us, we really appreciate it.Our Socialswww.adopaminekick.comFollow us on Instagramwww.instagram.com/adopaminekickLike us on Facebookwww.facebook.com/adopaminekickEmail us: adopaminekick@gmail.com Support the show

In this episode, Dr. Zach April returns to review the SSRI's. These are some of the best treatment options for mood. We talk about what to expect in general with these medications and review some of the individual medicines including sertraline (Zoloft), fluoxetine (Prozac) and escitalopram (Lexapro) to name a few.  A disclaimer, we're providing general guidance but everyone is different and you should always discuss with your health care professional management of any disease and therapy before trying anything you discover from a source on the internet (including this podcast)

A conversation about side effects of depression medicine. Enjoy :)

Dr. “So Good” SherwoodWEBSITE: http://doctorsogood.com-------------------------------------------The main aim of treatment with antidepressants is to relieve the symptoms of severe depression, such as feeling very down and exhausted, and prevent them from coming back. They are meant to make you feel emotionally stable again and help you to follow a normal daily routine.Selective serotonin reuptake inhibitors (SSRIs) are the most prescribed type of antidepressant and include: Fluoxetine. Citalopram. Sertraline.Serotonin in your brain regulates your mood. It's often called your body's natural “feel good” chemical. When serotonin is at normal levels, you feel more focused, emotionally stable, happier and calmer. Low levels of serotonin are associated with depression.Alternatives - Antidepressants•Talking therapies. Cognitive behavioral therapy. ...•Exercise. Research suggests that regular exercise may be a more effective treatment for mild depression than antidepressants. ...•Self-help groups. Talking through your feelings can be helpful. ...•Consistent sleep•Social media monitoring Supplements St. John's wortAshwagandha 5-HTPFull spectrum hemp (CBD)B6Amino acidsOmega 3 fatty acids DDHEA -------------------------------------------TO WATCH ALL FLYOVER CLIPS -https://banned.video/playlist/622553248186d152c5d07f5dSPONSORS FOR TODAY'S VIDEO►  ReAwaken America- text the word EVENTS to 40509(Message and data rates may apply. Terms/privacy: 40509-info.com)►  Kirk Elliott PHD - http://FlyoverGold.com ►  My Pillow - https://MyPillow.com/Flyover►. Z-Stack - https://flyoverhealth.com Own Your Own Business As An Option To Avoid The Jab- http://FlyoverCarpet.com https://TipTopK9.com/Want to help spread the Wake Up • Speak Up • Show Up -https://shop.flyoverconservatives.com/-------------------------------------------Follow our Social Media so we can be best friends

Dr. “So Good” SherwoodWEBSITE: http://doctorsogood.com-------------------------------------------The main aim of treatment with antidepressants is to relieve the symptoms of severe depression, such as feeling very down and exhausted, and prevent them from coming back. They are meant to make you feel emotionally stable again and help you to follow a normal daily routine.Selective serotonin reuptake inhibitors (SSRIs) are the most prescribed type of antidepressant and include: Fluoxetine. Citalopram. Sertraline.Serotonin in your brain regulates your mood. It's often called your body's natural “feel good” chemical. When serotonin is at normal levels, you feel more focused, emotionally stable, happier and calmer. Low levels of serotonin are associated with depression.Alternatives - Antidepressants•Talking therapies. Cognitive behavioral therapy. ...•Exercise. Research suggests that regular exercise may be a more effective treatment for mild depression than antidepressants. ...•Self-help groups. Talking through your feelings can be helpful. ...•Consistent sleep•Social media monitoring Supplements St. John's wortAshwagandha 5-HTPFull spectrum hemp (CBD)B6Amino acidsOmega 3 fatty acids DDHEA -------------------------------------------TO WATCH ALL FLYOVER CLIPS -https://banned.video/playlist/622553248186d152c5d07f5dSPONSORS FOR TODAY'S VIDEO►  ReAwaken America- text the word EVENTS to 40509(Message and data rates may apply. Terms/privacy: 40509-info.com)►  Kirk Elliott PHD - http://FlyoverGold.com ►  My Pillow - https://MyPillow.com/Flyover►. Z-Stack - https://flyoverhealth.com Own Your Own Business As An Option To Avoid The Jab- http://FlyoverCarpet.com https://TipTopK9.com/Want to help spread the Wake Up • Speak Up • Show Up -https://shop.flyoverconservatives.com/-------------------------------------------Follow our Social Media so we can be best friends

Download the cheat: https://bit.ly/50-meds  View the lesson: https://bit.ly/FluoxetineProzacNursingConsiderations    Generic Name Fluoxetine Trade Name Prozac Indication Depressive disorder, OCD, bulimia, panic disorder, bipolar, anorexia, ADHD, DM neuropathy, obesity Action Inhibits reuptake of serotonin allowing it to persist longer in the synaptic cleft Therapeutic Class Antidepressant Pharmacologic Class SSRI Nursing Considerations • Do not use while taking MAOIs • May cause suicidal thoughts, drowsiness, anxiety, sexual dysfunction, insomnia, palpitations • Monitor closely for serotonin syndrome • Concurrent use with certain medications may lead to QT prolongation • Monitor mood changes and assess for suicidal ideation • Monitor nutrition status • May cause elevated liver enzymes • Instruct pt to maintain good oral hygiene

Margie Taylor's son, Fort Hood Spc. Joey Lenz, 32, a tactical power generation specialist assigned to the 3rd Armored Brigade Combat Team, 1st Cavalry Division, was found dead in his barracks room on the morning of Feb. 1. 2022. Lenz, 32, who enlisted in 2017, was expected to leave the Army in mid-March. “He already had a job, he was happy, everything was good, and then he died,” she said. His mother said her son enjoyed his Army life, that he didn't want to leave, but he was being “pushed out.” Since his death, Taylor learned her son was being bullied and targeted by a captain who has since been moved. Taylor said Lenz's staff sergeant and the lieutenant colonel were also moved in recent weeks. Between Christmas, when her son visited her in Conroe, Texas for the holiday, and his death on Feb. 1st, Taylor was told her son has prescribed four medicines: Trazadone, Cyclobenzaprine, Fluoxetine, and Propranolol leading her to believe a drug reaction known as serotonin syndrome may have contributed to his death. During a memorial for Lenz at Fort Hood in February, Taylor said she met privately with over 30 soldiers who wanted to share happy memories of her son. "They said you need to get justice for Joey. They said, ‘We know he didn't just die. There's something going on and they overmedicate here.' Taylor said she was informed by Fort Hood CID Special Agent in Charge Maria Thomas that CID had completed its investigation and that her son had died of “mixed drug interaction.” “I believe there is more to the story,” Taylor said.

Bruce McArthur is a name that you likely know if you know a lot about True Crime in Canada. Bruce is known as the oldest known serial killer in Canadian history. This week, in part one, we will take a look at the early years of Bruce McArthur and the things that happened along the way to the crimes that he is more well known for. The interesting thing that you will discover is that the years that led up to Bruce becoming a serial killer are actually quite a bit different than the back-stories that you hear from others who wind up committing similar crimes. Bruce McArthur would end up being much older than most people are before something inside of him changed. Intro Music: "Recurring Anomaly" by Charles Holme  Sources:"Missing From The Village" By Justin Linghttps://www.thesun.co.uk/news/17606121/toronto-village-killer-bruce-mcarthur/https://toronto.ctvnews.ca/we-have-to-hold-them-to-it-mcarthur-assault-victim-hopeful-that-change-will-come-to-policing-1.5387839https://www.dailymail.co.uk/news/article-10635743/First-known-survivor-Toronto-serial-killer-Bruce-McArthur-speaks-out.htmlhttps://www.thestar.com/news/bruce-mcarthur.htmlhttps://roots-of-law.com/bruce-mcarthur-pleads-guilty-to-eight-counts-of-first-degree-murder/https://torontosun.com/news/local-news/hunter-what-made-serial-killer-bruce-mcarthur-tickhttps://toronto.ctvnews.ca/bruce-mcarthur-denies-assaulting-man-in-previously-unreleased-2016-police-interview-1.5647668https://www.thesun.co.uk/news/17606121/toronto-village-killer-bruce-mcarthur/https://en.wikipedia.org/wiki/2010%E2%80%932017_Toronto_serial_homicideshttps://en.wikipedia.org/wiki/Fluoxetine

Autism Expert and pioneer in the field of Autism, Psychologist and BCBA, Dr. Doreen Granpeesheh is answering viewer questions about chores, insurance ABA and more! Write in and leave a comment with your question for a chance to get it answered LIVE in real time! Or Check us out Later wherever you get your podcast!  https://www.autismnetwork.com/category/ask-dr-doreen/ https://www.tiktok.com/@askdrdoreen? 3:27 I'm panicking because my child graduates in 30 days What happens after there's no more school 13:15 Chores 13:51 Hi my son is 25. High functional. Bit when he comes at home after his work. he don't want to help in the house. I al sick and have to may help for mol the grass. He doesn't help cleaning. He wants you leave my house but he does not know administrative work. Don't kook. Doesn't clean. He's 25. 18:01 Insurance and costs associated with ABA 27:16 Good morning ladies, I was hoping you could give me some advice regarding sertraline. My son was previously on Fluoxetine for anxiety but was changed to Sertraline due to an increase in his OCD, started at 25mg now on 50mg. On the new tablet we are experiencing more anger, agitation and lack of interest in activities. Can sertraline cause these side effects? He's also takes guanfacine 2mg xx 29:58 Hi Dr. Doreen! My son is 28 months old, showing signs for ASD, also non verbal. I'm so overwhelmed and scared. Trying to help him before it's too late. Going to ABA (2,5h drive) for 12 hours a week. On a waitlist to get 24 hours but thats max what they are offering. afraid it won't be enough. Will it be successful to become his ‘therapist'? Learning ABA en skills he needs to develop. From Holland 36:25 ABA for higher functioning individuals. 42:16 Does anyone have a go to book for parents of newly diagnosed kiddos. I have a friend whose child was just diagnosed I'm not sure where to point them 50:25 It's been a minute since I dealt with the newly diagnosed. How can I help her the most? 52:10 Wondering what the medication is for a 3 1/2 yo that shows physical harm to others when denied access or told no. If ABA doesn't work to tame his aggression, what are our options? He had yeast belly and cdiff 58:25 ABA in Germany https://knospe-aba.com/en 58:23 Dr. Doreen on TikTok https://www.tiktok.com/@askdrdoreen? 59:34 This week on Autism Live! Link Tree https://linktr.ee/AutismLive Pre-Order the book written by the host of Autism Live, Shannon Penrod! https://www.amazon.com/Autism-Parent-Sanity-Saving-Spectrum/dp/1949177858 Apple Podcast: https://podcasts.apple.com/us/podcast/autism-live/id827968203 Twitch: https://www.twitch.tv/autismlivepodcast Spotify: https://open.spotify.com/show/0TXbDFs8cLP0UQbNVqHThf?si=VbEfw4_oRjqJY3vK2pgmFg IHeartRadio.com https://www.iheart.com/podcast/263-autism-live-51537613/ Audible: https://www.audible.com/pd/Autism-Live-Podcast/B08JJN7B28?qid=1611965289&sr=1-1&ref=a_search_c3_lProduct_1_1&pf_rd_p=83218cca-c308-412f-bfcf-90198b687a2f&pf_rd_r=M68PFW27AP000G4N9CCJ Google Podcast: https://podcasts.google.com/search/autism%20live  

Autism Expert and pioneer in the field of Autism, Psychologist and BCBA, Dr. Doreen Granpeesheh is answering viewer questions about chores, insurance ABA and more! Write in and leave a comment with your question for a chance to get it answered LIVE in real time! Or Check us out Later wherever you get your podcast!  https://www.autismnetwork.com/category/ask-dr-doreen/ https://www.tiktok.com/@askdrdoreen? 3:27 I'm panicking because my child graduates in 30 days What happens after there's no more school 13:15 Chores 13:51 Hi my son is 25. High functional. Bit when he comes at home after his work. he don't want to help in the house. I al sick and have to may help for mol the grass. He doesn't help cleaning. He wants you leave my house but he does not know administrative work. Don't kook. Doesn't clean. He's 25. 18:01 Insurance and costs associated with ABA 27:16 Good morning ladies, I was hoping you could give me some advice regarding sertraline. My son was previously on Fluoxetine for anxiety but was changed to Sertraline due to an increase in his OCD, started at 25mg now on 50mg. On the new tablet we are experiencing more anger, agitation and lack of interest in activities. Can sertraline cause these side effects? He's also takes guanfacine 2mg xx 29:58 Hi Dr. Doreen! My son is 28 months old, showing signs for ASD, also non verbal. I'm so overwhelmed and scared. Trying to help him before it's too late. Going to ABA (2,5h drive) for 12 hours a week. On a waitlist to get 24 hours but thats max what they are offering. afraid it won't be enough. Will it be successful to become his ‘therapist'? Learning ABA en skills he needs to develop. From Holland 36:25 ABA for higher functioning individuals. 42:16 Does anyone have a go to book for parents of newly diagnosed kiddos. I have a friend whose child was just diagnosed I'm not sure where to point them 50:25 It's been a minute since I dealt with the newly diagnosed. How can I help her the most? 52:10 Wondering what the medication is for a 3 1/2 yo that shows physical harm to others when denied access or told no. If ABA doesn't work to tame his aggression, what are our options? He had yeast belly and cdiff 58:25 ABA in Germany https://knospe-aba.com/en 58:23 Dr. Doreen on TikTok https://www.tiktok.com/@askdrdoreen? 59:34 This week on Autism Live! Link Tree https://linktr.ee/AutismLive Pre-Order the book written by the host of Autism Live, Shannon Penrod! https://www.amazon.com/Autism-Parent-Sanity-Saving-Spectrum/dp/1949177858 Apple Podcast: https://podcasts.apple.com/us/podcast/autism-live/id827968203 Twitch: https://www.twitch.tv/autismlivepodcast Spotify: https://open.spotify.com/show/0TXbDFs8cLP0UQbNVqHThf?si=VbEfw4_oRjqJY3vK2pgmFg IHeartRadio.com https://www.iheart.com/podcast/263-autism-live-51537613/ Audible: https://www.audible.com/pd/Autism-Live-Podcast/B08JJN7B28?qid=1611965289&sr=1-1&ref=a_search_c3_lProduct_1_1&pf_rd_p=83218cca-c308-412f-bfcf-90198b687a2f&pf_rd_r=M68PFW27AP000G4N9CCJ Google Podcast: https://podcasts.google.com/search/autism%20live  

Does SARS-CoV-2 infection have a lasting impact on brain structure? Find out about this and more in today's PV Roundup podcast.

Do COVID-19 vaccines offer more protection than natural immunity? Find out about this and more in today's PV Roundup podcast.

  Vidcast:  https://youtu.be/dVS7dUlRHo8   Those taking the antidepressant drug fluoxetine, branded as Prozac, have a significantly reduced risk of developing progressive age-related macular degeneration, the leading cause of blindness in those over the age of 50.  Researchers at the University of Virginia analyzed data from two health insurance databases covering more than 100 million persons after first studying the process leading to AMD and blindness in a mouse model.   The investigators, studying a group of already FDA approved drugs in the lab, showed that fluoxetine uniquely inhibits the inflammatory process leading to retinal degeneration due to its binding with an inflammatory molecule NLRP3-ASC.  Armed with this laboratory data, they wanted to see if fluoxetine conferred any clinical benefits for patients with AMD.     Using insurance databases that pinpointed those over the age of 50 with AMD who were taking Prozac and those who were not, analysis revealed that taking fluoxetine significantly slowed the AMD degenerative process.  Based on these results, the UVA ophthalmologists are looking forward to a clinical trial of fluoxetine in AMD patients.   https://www.pnas.org/content/118/41/e2102975118 https://www.sciencedaily.com/releases/2021/10/211021120941.htm   #amd #maculardegeneration #blindness #fluoxetine #prozac  

On Episode 8 of the Stroke Alert Podcast, host Dr. Negar Asdaghi highlights two articles from the September 2021 issue of Stroke: “Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor” and “Carotid Plaques From Symptomatic Patients Are Characterized by Local Increase in Xanthine Oxidase Expression.” She also interviews Drs. Jukka Putaala and Markku Kaste about their article “Should Tenecteplase be Given in Clinical Practice for Acute Ischemic Stroke Thrombolysis?”. Dr. Negar Asdaghi:         1) Are we ready to say goodbye to our old friend alteplase and replace it with a new one, tenecteplase, for acute stroke thrombolysis? 2) Does treatment of depression with SSRIs increase the risk of fractures in stroke patients? 3) When it comes to carotid intervention, should we continue offering treatment based on the degree of luminal stenosis, or are there better biomarkers in the horizon? These are some of the questions that we'll tackle in today's podcast. We're covering the best in Stroke. Stay with us. Dr. Negar Asdaghi:         Welcome back to Stroke Alert Podcast. My name is Negar Asdaghi. I'm an Associate Professor of Neurology at the University of Miami Miller School of Medicine and your host for the monthly Stroke Alert Podcast. For the September 2021 podcast, we have an exciting program where we discuss some of the controversies in stroke therapies. The September issue also contains a Focused Update with a set of articles and comprehensive reviews on the topic of genetics and stroke, organized by Professor Martin Dichgans, which I encourage you to review in addition to our podcast today. Later in today's podcast, I have the pleasure of interviewing Drs. Putaala and Kaste, from Helsinki Institute, to help us with a burning question of whether there's enough evidence now to use tenecteplase instead of alteplase for ischemic stroke thrombolysis. But first with these two articles. Dr. Negar Asdaghi:         Over a third of stroke survivors either have depressive symptoms or a formal diagnosis of depression. Selective serotonin reuptake inhibitors, or SSRIs, are the mainstay of depression treatment and the most common antidepressants prescribed in the U.S. In addition, in 2011, we had the results of the FLAME trial suggesting that early poststroke treatment with fluoxetine, a commonly prescribed SSRI, improves motor recovery and functional independence in stroke patients with motor deficit. Though these results were not replicated in the subsequent larger FOCUS trial, the use of SSRIs poststroke dramatically increased over the past decade. So what are the side effects of using SSRIs poststroke? It's a known fact that adult stroke survivors are more likely to experience bone fracture, and that there's some evidence that SSRIs may increase this risk. Dr. Negar Asdaghi:         So, in the current issue of the journal, Dr. Graeme Hankey and Joshua Jones, from Faculty of Health and Medical Sciences, University of Western Australia, in Perth, and colleagues aimed to answer this question with a systematic review and meta-analysis of randomized controlled trials that included an SSRI treatment for an adult patient with a previous hemorrhagic or ischemic stroke and included incident fractures, either as a primary or secondary study outcome, amongst other criteria. So they found four randomized controlled trials that fulfilled their research criteria. Three of them looked at the effects of fluoxetine, used at a dose of 20 mg per day for six months duration, on functional recovery and outcomes after stroke. And one trial, which has studied neuroregeneration in vascular protection by citalopram, either at a 10 mg or 20 mg daily dose also for six months duration, in patients with acute ischemic stroke. So three studies included with fluoxetine and one study included citalopram. Dr. Negar Asdaghi:         So, what they found was that although the risk of falls, seizures and recurrent stroke were not statistically increased with SSRI treatment, it was actually a significant increased risk of fractures with a risk ratio of 2.36 in patients treated with SSRI as compared to the placebo. Now, how the SSRIs will increase the risk of fractures is still unknown. There are multiple postulated mechanisms that are discussed in the paper, such as SSRIs potentially increasing spastic motor activity, causing orthostatic hypotension, dizziness, delayed reaction time or temporary imbalance or sleep disorders. But the most important mechanism to keep in mind is the possibility of SSRIs lowering bone mineral density. It's also important to note that the duration of exposure to SSRIs is an important predictor of factors. It's worth noting that the usual SSRI exposure in patients with the primary diagnosis of depression is a lot longer than the exposure time in these trials. Dr. Negar Asdaghi:         So, what are the top two takeaway points for stroke physicians? Number one: Fluoxetine and citalopram SSRIs, used for six months poststroke, double the risk of fracture as compared to placebo in this meta-analysis. Number two: While the mechanism of this association is still debated, fracture prevention should be an important discussion point when considering prescribing an SSRI to stroke patients. Dr. Negar Asdaghi:         We all know that carotid disease is a major cause of ischemic stroke. Now we have to keep in mind that the bulk of the literature in carotid disease are practically concentrated on the association between the degree of luminal stenosis and the risk of recurrent stroke. So, in practice, we constantly counsel and discuss risk of future ischemia in symptomatic and asymptomatic carotid disease based on the degree of stenosis that's less than 50%, or between 50% to 70%, or over 70%. Dr. Negar Asdaghi:         But what if we learn that some plaques can be active despite causing small or little stenosis? And conversely, some may be active despite being very large. There seems to be a growing literature that much of the recurrent strokes are occurring in destabilized plaques. And it turns out that there are actually biomarkers that could cause this destabilization, and we can actually measure them. Xanthine oxidase, or XO, is one of these biomarkers. XO is a key enzyme involved in degradation of purine into uric acid. Now I'm trying to simplify a complex subject here. Xanthine oxidase oxidizes the conversion of hypoxanthine into xanthine and xanthine into uric acid. Along the way, it also does create a whole bunch of reactive oxygen species such as superoxide and hydrogen peroxide, which can create tissue damage. Dr. Negar Asdaghi:         Now, how is XO and serum uric acid levels related to carotid disease? Well, it turns out that XO is enhanced in carotid arteries with evidence of atherosclerosis. Better yet, in animal models, inhibition of XO is associated with reduction in progression of atherosclerosis. So, in the current issue of the journal, Drs. Morsaleh Ganji and Valentina Nardi, from Departments of Cardiovascular Medicine and Anatomic Pathology of Mayo Clinic in Rochester, Minnesota, and colleagues set out to investigate whether carotid plaques from symptomatic patients had increased expression of xanthine oxidase than their asymptomatic counterparts. So, what they did was they looked at 88 patients undergoing carotid endarterectomy for symptomatic or asymptomatic carotid disease, part of the routine clinical practice, and then measured the XO expression by immunohistochemical staining in CA obtained specimens. Dr. Negar Asdaghi:         In addition, they collected a number of serum samples and other demographics and vascular risk factors from the participating patients. They found four major findings in their paper. Number one: XO expression was indeed higher in symptomatic carotid arteries. Number two: Symptomatic patients had a higher serum uric acid levels. Number three: Higher XO expression was inversely associated with the serum levels of HDL. Number four: The symptomatic plaques had higher amount of macrophages expressing XO. Dr. Negar Asdaghi:         Very interesting, but these findings were irrespective of the actual degree of luminal stenosis. In fact, the asymptomatic carotid plaques patients, as routine practice dictates, had a higher degree of luminal stenosis, but they had lower expression of XO and other associated findings. So what did we learn from this study? Well, there seems to be a strong association between certain biomarkers, in this case xanthine oxidase, and symptomatic state of carotid plaques, suggesting that perhaps in future we'll have other ways of measurements that may help us decide on carotid intervention rather than just the symptomatic state of the artery and the degree of stenosis. Dr. Negar Asdaghi:         It's been over 25 years since alteplase was approved as the thrombolytic agent of choice for treatment of patients with acute ischemic stroke. But in the past decade, tenecteplase, a genetically modified variant of alteplase with regulatory approval for treatment of ST-segment–elevation, myocardial infarction, has gained interest as an alternative reperfusion therapy for treatment of patients with acute ischemic stroke. Whether tenecteplase is ready to completely replace alteplase in clinical practice is certainly a burning question faced by the stroke community today. This was the subject of a lively debate at the most recent and entirely virtual 2021 International Stroke Conference, where a panel of experts reviewed the current evidence regarding the use of tenecteplase in acute ischemic stroke, examining data from animal models, preclinical studies to dose escalation studies and randomized trials, directly comparing tenecteplase with alteplase, as well as the collective clinical experience to date with this thrombolytic agent. Dr. Negar Asdaghi:         The proponents of change point out the many advantages of tenecteplase over alteplase, including its ease of use, increased fibrin specificity, longer half-time and its non-inferiority to alteplase in the head-to-head trials. On the other hand, the opponents caution stroke physicians, drawing attention to the inherent issues with the already completed clinical trials of tenecteplase, and argue that more data is needed before tenecteplase is considered as a thrombolytic agent of choice in routine clinical practice. Continuing on this debate in the September issue of the journal as part of the Controversies in Stroke series, Drs. Jeffrey Saver and May Nour provide opposing views to Drs. Dawn Kleindorfer and Mollie McDermott on the present evidence and current guidelines around tenecteplase use in acute ischemic stroke. Dr. Negar Asdaghi:         Acting as moderators, the senior authors of paper, Dr. Jukka Putaala, Head of Stroke Unit at Neurocenter, Helsinki University Hospital, and Dr. Markku Kaste, Emeritus Professor of Neurology at the University of Helsinki and past chairman of Neurocenter, Helsinki University Hospital, in Finland, provide us with the balancing remarks on the issue. I'm joined today by Professors Putaala and Kaste to give us an overview on the debate of tenecteplase versus alteplase. Is it time to make the switch? Good morning from sunny Florida and good afternoon to you both in Finland. Thank you for joining us on the podcast. I hope the weather is as beautiful in Helsinki today as it is here in Miami. Dr. Jukka Putaala:           Here it is not as warm as you have, but we have had a really beautiful summer, and at the moment, although it is also autumn, temperature is around 20 Celsius, so it's just great. Dr. Negar Asdaghi:         It's great to have you both. The paper outlines a generally recognized criteria to support the use of any new pharmacotherapy. Can you please start us off by reviewing the components of this criteria and tell us, please, how many checkmarks does TNK get on this checklist when considered as a reperfusion therapy in acute ischemic stroke? Dr. Jukka Putaala:           These eight criteria include a well-characterized mechanism of action; strong preclinical data; evidence of benefits and safety in a closely related clinical condition, which here is myocardial infarction; important practical advantages over existing agents; the clinical efficacy in how the patient has demonstrated in randomized trials; and endorsement by national practice guidelines. Also, support from regulatory authorities. And finally, clinical effectiveness, which has demonstrated in routine care. We think that tenecteplase for acute ischemic stroke meets actually all of these eight criteria. But we could also think that a smaller number of criteria will be enough to satisfy or meet, would be sufficient. Dr. Negar Asdaghi:         Perfect. So definitely many important steps, starting with the basics all the way to post-marketing clinical experience. Markku, now over to you. Can you remind us about the mechanism of action of tenecteplase? And what are some of the similarities and differences in terms of pharmacodynamic and pharmacokinetics with alteplase? Dr. Markku Kaste:           So alteplase catalyze plasminogen cleavage to plasmin and, in turn, degrades fibrin in thrombi, yielding clot lysis. TNK, compared to alteplase, is 14-fold greater fibrin activity and 80 times higher resistance to plasminogen activator inhibitor-1, which means it has a longer half-life, which is a major advantage. Patients need only one injection. In case you're compared to alteplase, when you had to have third dose injection and then one-hour infusion, which delay the care of patient, if the patient need thrombectomy. So it takes an hour for the infusion before patient can be transferred to thrombectomy, and time matters in brain infarction. So the faster you are, the better it is for patients. Dr. Negar Asdaghi:         Perfect. So more fibrin specificity, as you mentioned, and longer half-time for TNK. And in addition, TNK is not a new drug. In fact, there is over two decades' worth of experience with this in cardiology. Can you also tell us about this? And also some of the preclinical and animal studies that make TNK a potential candidate as a thrombolytic therapy in stroke? Dr. Markku Kaste:           In animal studies, both in vitro model of mural platelet deposits under arterial flow and a rabbit model using extracorporeal arterial-venous shunts, TNK was more potent, showing benefits up to three hours versus one hour when alteplase was used. So, it's a major benefit already in animal experiments and in the code team, of course, it will be transferred in clinical practice. So, in myocardial infarctions, in three randomized trials, including our 17,000 patients, TNK showed significant reduction for bleeding rates and similar intracerebral hemorrhage rates and 30-day mortality. Dr. Markku Kaste:           So, these facts support the use of TNK, also in ischemic stroke, the results from myocardial infarction, some steady encouraging. Although we have to keep in mind that myocardial infarction is very homogeneous disease, it's arterial occlusion, while ischemic stroke can be caused by the local occlusion just like myocardial infarction, but also from artery-to-artery thrombi or from a cardiac emboli. And these three [inaudible 00:17:43] mechanisms generate different kind of thrombi, so we need a better drug than alteplase, which really is effective, whatever is the etiology of the occlusion of brain artery. Dr. Negar Asdaghi:         Right. Thank you. Jukka, now over to you. Before we review the data from randomized trials of tenecteplase, can you please tell us about some of the practical advantages of tenecteplase over alteplase? We're comfortable with alteplase. Why should we make the switch? Dr. Jukka Putaala:           The key practical advantages arise from the fact that tenecteplase can be given as one single dose; it takes only one minute. And if you compare that to alteplase, you'll have to give the bolus first, and then following the bolus is 60 minutes infusion. And that also has many advantages in clinical practice, for example, if you have a patient with large vessel occlusion in a remote hospital, which is not thrombectomy-capable, you can give tenecteplase and then put the patient in the ambulance and transfer swiftly the patient to the thrombectomy center. While, when using alteplase, you have to start infusion, which you have to have the nursing staff that is capable of monitoring the infusion and taking care of any complications arising during the infusion and so forth. Dr. Jukka Putaala:           With tenecteplase, you can immediately transport the patient to a thrombectomy site after the bolus without any infusion-capable paramedics staff. Another practical advantage is that by using tenecteplase, you avoid the potential gap between the bolus and the infusion, which means that there is at least several minutes or longer gap in four out of five patients treated with alteplase. You can also think the other scenarios during this coronavirus era, and you have 15 patients with suspected or very fast coronavirus infection. By using bolus, you don't need to put nurses in the same room with the patients many times with the infusion if you use alteplase. Instead, you can use tenecteplase, it's only one single bolus, and you can go away and you don't have to be exposed to potential coronavirus infection. Dr. Negar Asdaghi:         So, many important advantages, as you mentioned. It seems very reasonable, then, to use tenecteplase in routine practice if it is indeed non-inferior to alteplase. Jukka, what dose of tenecteplase should be used for treatment of acute ischemic stroke patients? And we're definitely excited to hear about the head-to-head trials with tenecteplase versus alteplase. Dr. Jukka Putaala:           Well, the trial, the dose is 0.25 mg/kg or 0.4 mg/kg. It depends if you have LVO, if you review the evidence what we have now available, you have to use the lower dose in LVO patients. But you can use the higher dose in non-LVO patients. All of this arises from the evidence we have available right now. So, basically, five randomized trials have been completed, to date, comparing tenecteplase with alteplase in acute ischemic stroke. And shortly, if they pull out these five trials and compare primary outcome, which is modified Rankin Scale 0 to 1 versus prior, which means excellent outcome. Dr. Jukka Putaala:           So, when pulling out these five trials, 58% percent of patients rates excellent outcome versus 55% of alteplase, and this satisfied the criteria for non-inferiority. Regarding safety and secondary outcomes, major intracranial bleeding, mortality, this meta-analysis according to five trials shows similar results for tenecteplase and alteplase. You have to consider some details of this trial. I think Markku was going to quickly review some of the details of the science and doses used in these trials later on. Dr. Negar Asdaghi:         So, yes, this sounds great for tenecteplase, but so now over to you, Markku. As Jukka mentioned, do we hear a "not so fast for tenecteplase"? Is the current data enough to say goodbye to alteplase entirely and completely turn over to tenecteplase? What are some of the issues with the already completed trials? Dr. Markku Kaste:           It's not today, we cannot say goodbye to alteplase. As Jukka referred to those trials, there's no reason to go into these really deep details because the trials are quite small compared to ordinary clinical randomized trials studying stroke care. Like I don't want to give neuroprotection agents, for example. One larger trial was, let's say, reasonably well designed. But as to say that most of these trials are not really double-blind randomized clinical trials. And so the results which can be generated is not as reliable as double-blind trials because, of course, there are reasons, I mean, colleagues randomizing cases may think that, OK, a randomizing case and I'm not totally convinced about TNK. And I think this gentleman or this lady really needs effective thrombolytic agents, so I give alteplase, while if another patient with a mild symptom, same physician may think, OK, this stroke patient will recover no matter what, so let us randomize the patient. Dr. Markku Kaste:           So, it means these kind of unbalanced randomization provides data which is not really reliable. We had to have lots double-blinded randomized trials before it's time to say goodbye, if this double-blinded randomized trial verified that TNK beats alteplase. And, of course, we need also meta-analysis of those advanced trials, and these things can take time, although many guidelines, like AHA guidelines, European Stroke Organization guidelines, Chinese guidelines, Indian guidelines, they, in a way, how do you say, might recommend use of TNK, but I think we need more reliable scientific evidence before it's time to say goodbye to alteplase. Dr. Negar Asdaghi:         So, Jukka, Markku already alluded to this. I wanted you to review this for our listeners, the national practice guidelines and drug regulatory authority guidelines around the globe with regards to the issue of tenecteplase versus alteplase. Dr. Jukka Putaala:           Yeah, actually, already American, European, Chinese, Australian and Indian guidelines are recommending tenecteplase into the guidelines, which were recently published in 2019, between 2019 and 2021. What we can read from the guidelines is that tenecteplase can be considered over alteplase. But we have to remember that the strength of the recommendation will remain weak at present and quality of evidence is by the facts that we discussed of these five completely randomized trials and meta-analysis pulling out the data. Qualitative evidence remains slow, and, therefore, the wording in the guidelines is that it may be reasonable to choose or consider alteplase. Tenecteplase might be considered as an alternative to alteplase in certain conditions. Dr. Jukka Putaala:           The recommendations are a little bit mixed in the guidelines, but generally, in large vessel occlusions, the guidelines say that you could consider TNK over alteplase or even that you should consider TNK over alteplase in large vessel occlusion before proceeding to thrombectomy. However, in cases without large vessel occlusion, the statements are more mixed and they say tenecteplase might be considered or even that alteplase is preferred over tenecteplase until we have more evidence. Dr. Negar Asdaghi:         Thank you, Jukka. Markku, what should be our final takeaway message for the practicing stroke physicians at this point considering the use of tenecteplase in routine practice?   Dr. Markku Kaste:           Before your paper has been accepted and published in high-quality journal, it takes weeks, mostly it takes months, even a half a year. While in Stroke Conference, you get the most recent data, which is, let's say, generated last week or even the same day. So, when you want to really provide high-quality care of your patient, keep you updated. And then it's best for you and her, and it's better, of course, for your patient. International Stroke Conference and also European Stroke Conference, they are excellent places to get the most recent, yet unpublished, reliable information. Dr. Negar Asdaghi:         Professors Jukka Putaala and Markku Kaste, thank you for summarizing a large body of evidence for our listeners. We're definitely excited to learn how tenecteplase will ultimately stand against the old competitor and perhaps learn that both may be reasonable thrombolytic options, depending on the specifics of the clinical setting. Dr. Negar Asdaghi:         And this concludes our podcast for the September 2021 issue of Stroke. Please be sure to check the September table of contents for the full list of publications, including two special reports on consensus recommendations from the 11th STAIR Consortium, that is, Stroke Treatment Academic Industry Roundtable. Dr. Negar Asdaghi:         The first report is intended to enhance patient, clinician and policymaker comprehension at modified Rankin Scale findings in clinical trials and quality improvement initiatives. The second report from the STAIR Consortium is on top priorities for cerebroprotective studies, an important manuscript where the roundtable considered and presented a new paradigm for evaluation of putative therapies that may work together with recanalization treatments to improve outcome after ischemic stroke, with special attention to using the correct nomenclature, such as replacing the term "neuroprotection" with "cerebroprotection" when the intention of an investigation is to demonstrate that a new treatment benefits the entire brain, rather than neurons alone. Or replacing the term "time window" with "tissue window" or "target window" when selecting patients for recanalization therapies to enhance the notion that various elements of the neurovascular unit show vulnerability to ischemia evolving over different time scales in different brain regions. An important paradigm shift in ways we think of the brain under ischemic attack. With that, we invite you to continue to stay alert with Stroke Alert. Dr. Negar Asdaghi:         This program is copyright of the American Heart Association, 2021. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, visit AHAjournals.org.

Episode 33C-PTSD and Being Stuck in the MudNot the first time, probably  not the last.August 2, 2021This week I am talking about being “stuck in the mud”. I'm spinning my wheels and I got no traction. It's beginning to trouble me. The good news is that doing this podcast is regenerative for me. I know I have been really inconsistent these past couple of months, but I believe I am on the upswing after increasing my Fluoxetine to 40mg/day. This seems like an appropriate dose for the moment. Don't think that the medication is the only thing that is making a difference. I have had a lot of time to think and thinking I did. I thunk and I thunk and I thunk. Now I'm exhausted from all of the thinking.Today's episode: C-PTSD and Stuck in the Mud details these struggles as well as some ideas to break the logjam. I'm not completely out of the woods yet, but the sun is shining and my mood is improving, poco a poco. I am encouraged. If it weren't for this podcast, I would not be able to say this. I owe much of my improvement, which is marginal at best, to my listeners. You folks who consistently listen to Out of My Mind in Costa Rica. You have my heart and my dedication. Now, let me share a few websites that help to put an exclamation point onto this week's episode.My friend, the friend, whom I highlighted a couple of weeks ago, recommended a book by Pema Chӧdrӧn, entitled When Things Fall Apart. It is a Buddhist perspective on coming to terms with and resolving life's most painful moments. Its approach is familiar but the practices she described are revolutionary. Not to mention, they are extremely challenging to undertake.The Pema Chodron Foundation – The Buddhist Contemplative TraditionMichael G. Quirke, LMFT presents a very good article for those of you looking to establish a foundation for your recovery.Recovering from Complex PTSD: 3 Key Stages of Long-Term Healing (michaelgquirke.com)Suzanne Jessee, M.A. in Huntington Beach, CA provides another perspective on the 3 stages of C-PTSD recovery.The 3 Stages of Complex PTSD Recovery (theravive.com)Mandy Lo of TraumitizedAspie writes an excellent article covering a wide range of trauma information and recovery information. Check it out.How Does Complex PTSD Affect Interpersonal Relationships? – TraumatizedAspie.comDavid Joel Miller, MS, Licensed Therapist & Licensed Counselor provides some great guidance on how to tread your path of healing. Given the complexity and interpersonal nature of Complex-PTSD, it is critical to be patient and pay attention to the little things.6 ways to recover from Complex Trauma or Complex PTSD | counselorssoapbox

Brad and Chris the Pharmacist discuss the benefits and side effects of depression medications: Fluoxetine (Prozac) & Sertraline (Zoloft). Patient Resources National Alliance on Mental Illness www.nami.org 1-800-950-NAMI Anxiety and Depression Association of America www.adaa.org National Institute of Mental Health www.ninh.nih.gov Help Finding a Therapist 1-800-THERAPIST National Suicide Prevention Lifeline 1-800-273-TALK American Psychological Association Crisis Text Line Text HOME to 741741 Medical Disclaimer All information, content, and material of this website is for informational purposes only and are not intended to serve as a substitute for the consultation, diagnosis, and/or medical treatment of a qualified physician or healthcare provider. Affiliate disclaimer: Keep in mind that we may receive commissions when you click our links and make purchases. However, this does not impact our reviews and comparisons. We are highly selective in our products and try our best to keep things fair and balanced in order to help you make the best choice for you.

  Vidcast:  https://youtu.be/M1HUN0PAXYw   The FDA and Dash Xclusive now recall Imperia Elita Vitaccino Coffee Weight Loss and Anxiety Dietary Supplement.  This product contains the undisclosed prescription drugs sibutramine and fluoxetine.  Silbutramine, an appetite suppressant, was withdrawn from the market due to safety issues including induction of heart attack and stroke.  Fluoxetine, branded as Prozac, can trigger psychosis and suicide and must be used under supervision.  If you bought this product, stop using it and return it to the point of purchase.  Questions to Dash Xclusive by email Dashxclusive11@gmail.com.   https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/dash-xclusive-issues-voluntary-nationwide-recall-imperia-elita-vitaccino-coffee-due-presence   #vitaccino #diet #anxiety #sibutramine #fluoxetine #recall  

Episode 25C-PTSD and Baby StepsAm I Feeling Better or Is It Prozac?April 29, 2021 In this episode, I am talking about feeling better on a more consistent way. This enhancement in my mood also corresponds to the window of effectiveness for Fluoxetine which is better known as Prozac. It doesn't matter to me because the experience of feeling better is motivating regardless of it's source. My role is to build on that emotional and cognitive shift taking place into a better world for myself and for the people I love and care about.I am taking Prozac, which is classified as a Selective Serotonin Reuptake Inhibiter or an SSRI. This class of anti-depressant has been shown to be just as effective in treating depression as psychotherapy. There are currently 15 different name brands of SSRIs using six fundamental compounds. For more information click on any of the links below.Lexapro (escitalopram),  Zoloft (sertraline), Prozac (fluoxetine), Paxil (paroxetine), Celexa (citalopram), Luvox (fluvoxamine), Paxil CR (paroxetine), Brisdelle (paroxetine), Sarafem (fluoxetine), Luvox CR (fluvoxamine), Prozac Weekly (fluoxetine), Pexeva (paroxetine), Selfemra (fluoxetine), and Rapiflux (fluoxetine).In the Costa Rican healthcare system, I was given the choice of Prozac, Prozac or Prozac. So, I chose Prozac.Dr. Arielle Schwarts has been writing about the journey of healing from Complex-PTSD for years. Healing Complex PTSD and Dissociation | Dr. Arielle Schwartz (drarielleschwartz.com)Here is the official government site on PTSD. I have given you the link to their information on Complex-PTSD.Complex PTSD - PTSD: National Center for PTSD (va.gov)I have given you this resource before. It's an oldie, but a goodie.Complex PTSD Healing | CPTSDfoundation.orgThrive After Abuse has a YouTube Channel and they are doing their part in helping people with Complex-PTSD. Healing from Complex PTSD: Relaxation and Affirmation Video - YouTube

Well, it all starts with a story, doesn't it? And one of the stories is my story. And I'll just you know, people's stories are so important. And I know that everybody out there has a really strong story. And I'd love to hear everybody's stories because I get so much encouragement from hearing people's strengths and courage and just fighting the battle. And so I'm just going to share a little bit about my story and how I got to the things that I'm doing right now. I'm pretty much I was diagnosed with anxiety and depression at the beginning of my medical training, which was hospital training where we didn't sleep, you know. We were expected to sleep maybe two or three hours, and then take care of patients. We would have terrible long, ugly shifts in the hospital. You know, at that time, back in the 90s, all the medical profession knew to do for me, was to give me vitamin P, which was vitamin Prozac or vitamin Fluoxetine as we call it here in New Zealand. And I thought, “Okay, this is just what I got to do. And I would take my pill and I'd be able to function as a doctor and do what my heart wanted to do ever since I was five years old, And that was to be a doctor and help people.”So I was on that road and I just took my medicine and sometimes I'd rebel and come off my medicine. I'd do okay, and then I wouldn't do okay, and then I come back on my medicine. And then I remember I was off my medicine. My husband and I and our daughters had come back from a long trip from ......Download & Listen for the Rest of the Story! How to Support the Mission of the Show?1. Be a Hero and tell a friend and loved one about the MD and Chef Team podcast. They will surely thank you. 2. Join the FREE and Private "Bossy Brain Solution" FB Live Weekly Coaching Group. This is where we do weekly coaching sessions and have a community that inspires each other to be better in health and life.https://www.facebook.com/groups/bossybrainsolution3. For daily insights, inspiration, and behind the scenes action, follow us on Instagram and Facebook; just look for Doctoronamission (Dr. Isabel MD)https://www.facebook.com/doctoronamission/https://www.instagram.com/doctoronamission4. Apple users, please subscribe and review our show on Apple podcasts, we read them all. Android users, subscribe to our show on Google podcasts. Subscribers never miss any of the action!LinkedIn: https://nz.linkedin.com/in/doctoronamissionPinterest: https://www.pinterest.nz/mdandchefteam/ Support the show (https://www.buymeacoffee.com/mdandchefteam)

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.10.12.336941v1?rss=1 Authors: Mukhopadhyay, S., Chatterjee, A., Tiwari, P., Ghai, U., Vaidya, V. A. Abstract: Elevation of serotonin via postnatal fluoxetine (PNFlx) treatment during critical temporal windows is hypothesized to perturb the development of limbic circuits thus establishing a substratum for persistent disruption of mood-related behavior. We examined the impact of PNFlx treatment on the formation and maintenance of perineuronal nets (PNNs), extracellular matrix (ECM) structures that deposit primarily around inhibitory interneurons, and mark the closure of critical period plasticity. PNFlx treatment evoked a significant decline in PNN number, with a robust reduction in PNNs deposited around parvalbumin (PV) interneurons, within the CA1 and CA3 hippocampal subfields at postnatal day 21 in Sprague-Dawley rat pups. While the reduction in CA1 subfield PNN number was still observed in adulthood, we observed no change in colocalization of PV-positive interneurons with PNNs in the hippocampi of adult PNFlx animals. PNFlx treatment did not alter hippocampal parvalbumin, calretinin, or reelin-positive neuron numbers in PNFlx animals at P21 or in adulthood. We did observe a small, but significant increase in somatostatin (SST)-positive interneurons in the DG subfield of PNFlx-treated animals in adulthood. This was accompanied by altered GABA-A receptor subunit composition, increased dendritic complexity of apical dendrites of CA1 pyramidal neurons, and enhanced neuronal activation revealed by increased c-Fos-positive cell numbers within hippocampi of PNFlx-treated animals in adulthood. These results indicate that PNFlx treatment alters the developmental trajectory of PNNs within the hippocampus, raising the possibility of a disruption of critical period plasticity and the establishment of an altered excitation-inhibition balance within this key limbic brain region. Copy rights belong to original authors. Visit the link for more info

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.07.26.221648v1?rss=1 Authors: Ramsteijn, A. S., Verkaik-Schakel, R. N., Houwing, D. J., Plosch, T., Olivier, J. D. A. Abstract: Many pregnant women experience symptoms of depression, and are often treated with selective serotonin reuptake inhibitor (SSRI) antidepressants, such as fluoxetine. In utero exposure to SSRIs and maternal depressive symptoms is associated with sex-specific effects on the brain and behavior. However, knowledge about the neurobiological mechanisms underlying these sex differences is limited. In addition, most animal research into developmental SSRI exposure neglects the influence of maternal adversity. Therefore, we used a rat model relevant to depression to investigate the molecular effects of perinatal fluoxetine exposure in male and female juvenile offspring. We performed RNA sequencing and targeted DNA methylation analyses on the prefrontal cortex and basolateral amygdala; key regions of the corticolimbic circuit. Perinatal fluoxetine enhanced myelin-related gene expression in the prefrontal cortex, while inhibiting it in the basolateral amygdala. SSRI exposure and maternal adversity interacted to affect expression of genes such as myelin-associated glycoprotein (Mag) and myelin basic protein (Mbp). We speculate that altered myelination reflects altered brain maturation. In addition, these effects are stronger in males than in females, resembling known behavioral outcomes. Finally, Mag and Mbp expression correlated with DNA methylation, highlighting epigenetic regulation as a potential mechanism for developmental fluoxetine-induced changes in myelination. Copy rights belong to original authors. Visit the link for more info

  Vidcast:  https://youtu.be/auJkLEufIU4   The selective serotonin reuptake inhibitor fluoxetine, branded as Prozac and Saracen and prescribed for depression, obsessive compulsive disorder, eating problems, and panic issues turns out to significantly slow the replication of the novel coronavirus in tissue culture.  The drug works at concentrations typically found in patients using this medication.   Virologists at Germany’s University of Würzburg discovered this phenomenon during their screening of already marketed prescription drugs for anti-CoVid19 activity.  Although Prozac was effective, other popular selective serotonin reuptake inhibitors including Lexapro and Paxil failed to have this effect.  Prozac did not inhibit other viruses including herpes, RSV, or rabies.   The researchers hope that Prozac may prove to be therapy for early stages of CoVid.   https://www.biorxiv.org/content/10.1101/2020.06.14.150490v2.full.pdf   #covid #prozac #fluoxetine #ssri  

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.06.12.147876v1?rss=1 Authors: Villani, C., Sacchetti, G., Carli, M., Invernizzi, R. W. Abstract: Motor skill is a specific area of disability of Rett syndrome (RTT), a rare disorder occurring almost exclusively in girls, caused by loss-of-function mutations of the X-linked methyl-CpG-binding protein2 (MECP2) gene, encoding the MECP2 protein, a member of the methyl-CpG-binding domain nuclear proteins family. Brain 5-HT, which is defective in RTT patients and Mecp2 mutant mice, regulates motor circuits and SSRIs enhance motor skill learning and plasticity. In the present study, we used heterozygous (Het) Mecp2 female and Mecp2-null male mice to investigate whether fluoxetine, a SSRI with pleiotropic effects on neuronal circuits, rescues motor coordination deficits. Repeated administration of 10 mg/kg fluoxetine fully rescued rotarod deficit in Mecp2 Het mice regardless of age, route of administration or pre-training to rotarod. The motor improvement was confirmed in the beam walking test while no effect was observed in the hanging-wire test, suggesting a preferential action of fluoxetine on motor coordination. Citalopram mimicked the effects of fluoxetine, while the inhibition of 5-HT synthesis abolished the fluoxetine-induced improvement of motor coordination. Mecp2 null mice, which responded poorly to fluoxetine in the rotarod, showed reduced 5-HT synthesis in the prefrontal cortex, hippocampus and striatum, and reduced efficacy of fluoxetine in raising extracellular 5-HT as compared to female mutants. No sex differences were observed in the ability of fluoxetine to desensitize 5-HT1A autoreceptors upon repeated administration. These findings indicate that fluoxetine rescues motor coordination in Mecp2 Het mice through its ability to enhance brain 5-HT and suggest that drugs enhancing 5-HT neurotransmission may have beneficial effects on motor symptoms of RTT. Copy rights belong to original authors. Visit the link for more info

Obesity is a problem worldwide and several Cochrane Reviews examine interventions that might help to prevent or reduce it. These were added to in October 2019 with a new review examining the evidence on the drug fluoxetine. Here’s the lead author, Alejandro Gonzalez Garay from the National Institute of Paediatrics in Mexico City to let us know what they found.

Obesity is a problem worldwide and several Cochrane Reviews examine interventions that might help to prevent or reduce it. These were added to in October 2019 with a new review examining the evidence on the drug fluoxetine. Here’s the lead author, Alejandro Gonzalez Garay from the National Institute of Paediatrics in Mexico City to let us know what they found.

Obesity is a problem worldwide and several Cochrane Reviews examine interventions that might help to prevent or reduce it. These were added to in October 2019 with a new review examining the evidence on the drug fluoxetine. Here’s the lead author, Alejandro Gonzalez Garay from the National Institute of Paediatrics in Mexico City to let us know what they found.

A myriad of nightly thoughts, powered by Anxiety and Depression, in partnership with Xanax...and Fluoxetine.

This month - with about 1 in 10 people in the UK on antidepressant drugs, we're asking what's it like to come off of these medications? How well is this change managed? And how can this be improved? Like this podcast? Please help us by supporting the Naked Scientists

This month - with about 1 in 10 people in the UK on antidepressant drugs, we're asking what's it like to come off of these medications? How well is this change managed? And how can this be improved? Like this podcast? Please help us by supporting the Naked Scientists

Fluoxetine is an SSRI used in the management of depression, anxiety, OCD, PTSD, and other psychiatric conditions. Fluoxetine has a very long half-life which can impact clinical management. I discuss how this matters in this podcast episode. Fluoxetine inhibits CYP2D6 which can alter the concentrations of many drugs. Prodrugs like codeine and tamoxifen can have their effects reduced because of fluoxetine. I explain this further in the episode. By inhibiting CYP2D6 concentrations of many drugs can be raised by the use of fluoxetine.

Editor's Summary by Jody Zylke, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the October 22, 2019 issue

There continues to be widespread concerns over shortages of critical psychiatric drugs for mental health patients in Gautend and across the country. The drugs in short supply are (include Fluoxetine and Citalopram) both critical inhibitors that ease symptoms of moderate to severe depression. Mental health patients are being told that essential drugs are in short supply or inadequate in supply and told to come back later in government hospitals and clinics.

On MIA Radio this week, MIA's Zenobia Morrill interviews Dr. Vance Trudeau, a professor at the University of Ottawa in Canada. Dr. Trudeau describes a recent study he conducted, alongside a team of researchers, led by Dr. Marilyn Vera-Chang, that has implications for understanding of the long-term impact of antidepressant drug exposure (see MIA report). The study, titled Transgenerational hypocortisolism and behavioral disruption are induced by the antidepressant fluoxetine in male zebrafish Danio rerio linked antidepressant exposure to decreased coping behaviors in zebrafish that lasted several generations. Dr. Trudeau is the research chair in neuroendocrinology at the University of Ottawa, where he studies how the brain regulates hormonal activity in fish and frogs. Such analyses offer important insights into the effects of environmental exposures on human health because these hormonal systems are shared across species. © Mad in America 2019

Porpoise Crispy Podcast Volume #8 Episode #3 Fluoxetine (Prozac, Sarafem) Curated by Sunny Irackbeasts (Paddy and Jay) February 25, 2019       V8N2 decapitated Pontiac 87 Preoccupations Pontiac 87 Single Wheel of Fortune Promartyr Consolation EP Into The Trees Still Corners Creatures of an Hour Sections Sen Morimoto Cannonball! August Twelve Khruangbin The Universe Smiles Upon You        Untitled Break for Michael Jackson to Sing Not My Fault Goodbye Blue Monday The World Won't Listen Lupine Ossuary Thee Oh Sees Mutilator Defeated At Last Emotional Haircut LCD Soundsystem American Dream You Let My Tyres Down Tropical Fuck Storm A Laughing Death In Meatspace Bedside Table Bedhead Whatfunlifewas?       Untitled Break for Nicaragua A Sort of Homecoming U2 The Unforgettable Fire      V8N3 Frankensteined   The pCrispy is only an hour of music so I know you’ve got time to enjoy to these bad asses of the Internets:  The Westerino Show Funkytown Bayerclan Squirreling Podcast Secretly Timid    

Jonathan Gravel, family medicine resident at the University of Toronto, is joined by Matthew Jefkins, internal medicine resident at Queen's University, on this week's episode of The Rounds Table. Together they are covering the use of haloperidol and ziprasidone for delirium in critical illness and fluoxetine on functional outcomes after acute stroke (FOCUS trial). Delirium affects ... The post Mind Over Matter: Antipsychotics for Intensive Care Unit-Associated Delirium and Fluoxetine after Acute Stroke appeared first on Healthy Debate.

Jonathan Gravel, family medicine resident at the University of Toronto, is joined by Matthew Jefkins, internal medicine resident at Queen's University, on this week's episode of The Rounds Table. Together they are covering the use of haloperidol and ziprasidone for delirium in critical illness and fluoxetine on functional outcomes after acute stroke (FOCUS trial). Delirium affects ...The post Mind Over Matter: Antipsychotics for Intensive Care Unit-Associated Delirium and Fluoxetine after Acute Stroke appeared first on Healthy Debate.

A Small Dose explores Fluoxetine, and how it is used to treat depression and other mood disorders. www.asmalldose.com

This week, Dr. Nirav Shah and I talk about antidepressants -- SSRIs specifically -- in Stroke Recovery. The FLAME study demonstrated the benefits to motor recovery. SSRI stands for Selective Serotonin Re-uptake Inhibitor. Basically, the way data gets sent from one nerve cell to another is through the use of chemicals, like serotonin. The body produce serotonin and the collects it when done, taking it out of the system. An SSRI slows down the collection process -- it inhibits the re-uptake. That leaves more serotonin floating around the brain. Having more serotonin floating around the brain can help reduce, manage, or eliminate depression and other conditions. That's why SSRIs are some of the most common anti-depressants on the market. The FLAME study looked at how Fluoxetine (AKA Prozac) behaves in folks who recently had a stroke. Fluoxetine is an old school antidepressant and SSRI. The study appeared to show that the extra serotonin in the brain may help promote neuroplasticity and recovery of motor skills after stroke, and that's why we're talking about it today. My Experience When I was inpatient, the doctor put me on an SSRI due to the FLAME study. She tried Prozac (AKA Fluoxetine) first. Unfortunately, it gave me an anxiety attack. On the other hand, I now know what an anxiety attack feels like. Not pleasant. A Xanax took care of that. We tried again the next day, this time with another SSRI called Lexapro (AKA Escitalopram). Someone explained to me that the molecule that makes up Lexapro is the mirror image of the Prozac molecule. I'd had Lexapro in the past, with no ill effects so it was worth a shot. Success! No anxiety attack this time. And that's how an SSRI earned a spot in my daily collection of medication. But did it help my recovery? Maybe. There's no way to tell for sure. The data indicates that it should and there is no reason to think it didn't help. As a side effect, I did not go into the deep depression so common among other stroke survivors. This is a new use for SSRIs, Fluoxetine, and Escitalopram. It's borderline off-label. Not all doctors are familiar with the idea that SSRIs promote the neuroplasticity that supports recovery of motor functions. And that's how I ended up explaining the research to my primary care physician as he reviewed my meds with me post-hospital. The FLAME study covered 6 months. I'm still taking the Lexapro today. When I talked to my rehab doctor about whether I should continue we concluded that since I don't have any negative results from it, we may as well keep it up. If there's a chance it can help, and it's not hurting, then that sounds good to me. Dr. Nirav H. Shah Dr. Nirav H. Shah is a fellowship trained neurologist and sub-specialist in cerebrovascular and stroke medicine with board certifications in t: neurology, stroke medicine, carotid neurosonology, transcranial doppler ultrasound, and neuroimaging. He is a practicing neurohospitalist and served as the stroke medical director at Swedish Medical Center in Seattle. Academically, he is interested in emergent and critical care neurology research and is an associate editor for The Neurohospitalist, a peer-reviewed journal. He enjoys mentoring trainees and collaborating on publications and conference presentations. Outside of clinical care Dr Shah is collaborating with experts to develop scalable technologies capable of ameliorating healthcare’s challenges. He consults with startups and investors to develop technologies and devices so that one day they are available to his patients. He has worked with companies to meet FDA regulations for approval as well as to help them understand the provider perspective of product-market fit. Dr. Shah is also the CEO and Founder of Sentinel Healthcare. He is also a passionate traveler and photographer. So let's fan the FLAME of stroke recovery with Nirav. Hack of the Week Many stroke survivors use a day of the week pill organizer to keep track of meds. And, sometimes, the day of the week. The organizer can also make it easy to keep track of whether or not we've taken pills for the day. After taking your pills, leave the door for that day open exposing the now empty chamber. That gives you and your caregiver an easy to see visual queue the deed is done.   Links FLAME study Presentation http://www.my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_427770.pdf Efficacy of Fluoxetine - a Trial in Stroke (EFFECTS) https://clinicaltrials.gov/ct2/show/NCT02683213 Predicting recovery in acute poststroke aphasia https://www.ncbi.nlm.nih.gov/pubmed/29451321 Nirav’s previous appearance http://strokecast.com/nirav Nirav on Stem Cells and Stroke Recovery http://strokecast.com/stemcells Nirav  on LinkedIn https://www.linkedin.com/in/nirav-h-shah/ Nirav at Swedish https://www.swedish.org/swedish-physicians/profile.aspx?name=nirav+h+shah&id=271893 Nirav on Twitter http://twitter.com/NeuroNirav The Neurohospitalist http://journals.sagepub.com/home/nho Nirav’s Photography www.thoughtpotential.com Sentinel Healthcare http://www.sentinel.healthcare/ Where do we go from here? Check out the links to the FLAME study and the other SSRI stroke studies above. Subscribe to Strokecast for free in your favorite podcast app. Use your pill box door as a reminder/calendar. Don't get best…get better.

In this episode, we discuss the importance of accurately recognizing depressive symptoms in patients with kidney disease and provide review the limited available literature regarding treatment in this population. We then discuss guidelines to determine some of the best treatment options for this unique subgroup of patients.

The post Fluoxetine (Prozac) Nursing Pharmacology Considerations appeared first on NURSING.com.

This is the Emotional Freedom Techniques EFT Tapping Recording for Podcast 11

prozac,ssri,medical treatment,Antidepressants,SSRIs,fluoxetine Prozac,fluvoxamine,Luvox,sertraline,Zoloft - There are so many choice when it comes to medication with OCD. How affective are they? Should I use them? Find out more, listen to this podcast for ideas...

Andrea Cipriani from the University of Oxford, UK, discusses the efficacy of antidepressants for children and adolescents.

Dr Krystal and Chris KP join Dr Shane in the studio.First guest is Professor Dick Strugnell who is a microbiologist with the University of Melbourne and the Doherty Institute. He is decoding the genome of superbug Klebsiella pnuemonaie, a bacterium found in hospitals throughout the world. The study could give rise to a vaccine or alternative treatment to antibiotics, which are starting to fail against this bacteria.Second guest is Dr. Ricardo Costa, Department of Nutrition and Dietetics from Monash University, in the studio to talk about extreme exercise and the link to blood poisoning.Researchers have discovered that extreme exercise can cause intestinal bacteria to leak into the bloodstream, which then triggers a systemic inflammatory response from the body's immune cells, similar to a serious infection episode. Molly O'Sullivan, from Murdoch Childrens Research Institute, in to discuss a study on Selective Serotonin Reuptake Inhibitors (SSRIs) treatment for autism.The purpose of the study is to evaluate Fluoxetine, a commonly used SSRI, to see how safe and effective this drug is for young people aged 7.5 to 18 years with an autism spectrum disorder.The study have not yet reached the target goal of 146 participants. The study team is determined to reach the target sample size, if you're interested in being a participant contact molly.osullivan@mcri.edu.au.

The post Fluoxetine (Prozac) appeared first on NURSING.com.

Interview with Robin B. Jarrett, PhD and Michael E. Thase, MD, authors of Preventing Depressive Relapse and Recurrence in Higher-Risk Cognitive Therapy Responders: A Randomized Trial of Continuation Phase Cognitive Therapy, Fluoxetine, or Matched Pill Placebo

This audio program summarizes how to teach supportive psychotherapy; continuation treatment with fluoxetine in treatment-responsive children and adolescents; a group treatment program for borderline personality disorder; regional expression of GABA-related genetic transcripts in the neocortex of schizophrenia patients; the relationship between cannabis use and loss of brain volume in schizophrenia; and the association of nicotine dependence with low dopamine D2 receptor availability in the striatum. Articles can be viewed online at www.ajp.psychiatryonline.org.